Mr. Yu Shan is an Executive Director, General Manager and Vice President of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or “Hepalink”). He is also a Co-Founder of the company and a member of the group management council in charge of business development, external affairs, and safety management.

Since co-founding Hepalink in 1998, Mr. Shan provided vital leadership that has brought the company uninterrupted profitability and the successful listing in both mainland China and Hong Kong. Meanwhile, the company’s lead product, enoxaparin sodium injection, as the first generic enoxaparin in China and the EU, is now sold to over 40 countries and regions around the world, achieving widespread recognition in markets with high entry standards. Under its co-founders’ effective leadership, Hepalink has built a vibrant ecosystem of synergistic businesses in heparin industrial chain, CDMO services, and innovative drugs.

Furthermore, Mr. Shan has made integral contributions to the building and development of Hepalink’s manufacturing sites, including the Duopule site, and the Pingshan Industrial Park. Last but not least, Mr. Shan also developed Hepalink’s strategic planning capabilities leading the corporate strategy development for the company.

Before founding Hepalink, Mr. Shan was General Manager at Shenzhen Yuanzheng Pharmaceutical Co., Ltd. Prior to that, he worked at the Chinese Institute of Atomic Energy.

Mr. Shan has a Bachelor of Science degree from Peking University.